Conventional and novel PET tracers for imaging in oncology in the era of molecular therapy.

[1]  B. Kramer,et al.  Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Uwe Haberkorn,et al.  Comparison of the pharmacokinetics of 68Ga-DOTATOC and [18F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[3]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[4]  Uwe Haberkorn,et al.  Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. , 2003, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.

[5]  A. Runz,et al.  Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[6]  C. Nanni,et al.  11C/18F-choline PET or 11C/18F-acetate PET in prostate cancer: may a choice be recommended? , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[7]  Sven N. Reske,et al.  Experience with carbon-11 choline positron emission tomography in prostate carcinoma , 2000, European Journal of Nuclear Medicine.

[8]  J. Kotzerke,et al.  Is 11C-choline the most appropriate tracer for prostate cancer? , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[9]  L. Schwartz,et al.  Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  H. Hoekstra,et al.  Positron emission tomography in patients with breast cancer using (18)F-3'-deoxy-3'-fluoro-l-thymidine ((18)F-FLT)-a pilot study. , 2006, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[11]  A. D. Dei Tos,et al.  Assessing epidermal growth factor receptor expression in tumours: what is the value of current test methods? , 2005, European journal of cancer.

[12]  E. Nitzsche,et al.  Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumors. , 2001, Radiology.

[13]  T. Higuchi,et al.  Positron emission tomographic imaging with11C-choline in differential diagnosis of head and neck tumors: comparison with18F-FDG PET , 2004, Annals of nuclear medicine.

[14]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[15]  S. Groshen,et al.  Molecular determinants of cetuximab efficacy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Barrio,et al.  Positron emission tomography imaging of adenoviral-mediated transgene expression in liver cancer patients. , 2005, Gastroenterology.

[17]  G. Rosner,et al.  Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[19]  Wolfgang A Weber,et al.  11C-methionine PET improves the target volume delineation of meningiomas treated with stereotactic fractionated radiotherapy. , 2006, International journal of radiation oncology, biology, physics.

[20]  P. Conti,et al.  Synthesis and preliminary evaluation of 9-(4-[18F]-fluoro-3-hydroxymethylbutyl)guanine ([18F]FHBG): a new potential imaging agent for viral infection and gene therapy using PET. , 1998, Nuclear medicine and biology.

[21]  T. Hara.  11C-choline and 2-deoxy-2-[18F]fluoro-D-glucose in tumor imaging with positron emission tomography. , 2002, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.

[22]  Eyal Mishani,et al.  Assessment of malignant skeletal disease: initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[23]  Y. Nishiyama,et al.  Correlation of 18F-FLT and 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[24]  N. Normanno,et al.  Epidermal growth factor-related peptides and their receptors in human malignancies. , 1995, Critical reviews in oncology/hematology.

[25]  D. Rubello,et al.  Sequential FDG-PET/CT reliably predicts response of locally advanced rectal cancer to neo-adjuvant chemo-radiation therapy , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[26]  Xin Huang,et al.  Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial , 2006, The Lancet.

[27]  David W Townsend,et al.  Time Course of Early Response to Chemotherapy in Non–Small Cell Lung Cancer Patients with 18F-FDG PET/CT , 2007, Journal of Nuclear Medicine.

[28]  U. Haberkorn,et al.  PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[29]  Z. Lengyel,et al.  Detection of prostate cancer with 11C-methionine positron emission tomography. , 2005, The Journal of urology.

[30]  Michael E Phelps,et al.  Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography. , 2006, Chest.

[31]  Haesun Choi,et al.  We should desist using RECIST, at least in GIST. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  J. Barrio,et al.  Evaluation of the skeletal kinetics of fluorine-18-fluoride ion with PET. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[33]  Michael E Phelps,et al.  Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3'-deoxy-3'-18F-fluorothymidine PET. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[34]  J. Reubi,et al.  Affinity profiles for human somatostatin receptor subtypes SST1–SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use , 2000, European Journal of Nuclear Medicine.

[35]  Torsten Mattfeldt,et al.  3-deoxy-3-[(18)F]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. , 2002, Cancer research.

[36]  Harvey Mamon,et al.  FDG-PET/CT Tumor Segmentation-Derived Indices of Metabolic Activity to Assess Response to Neoadjuvant Therapy and Progression-Free Survival in Esophageal Cancer: Correlation With Histopathology Results , 2007, American journal of clinical oncology.

[37]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[38]  Sirong Chen,et al.  Dual-Tracer PET/CT Imaging in Evaluation of Metastatic Hepatocellular Carcinoma , 2007, Journal of Nuclear Medicine.

[39]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[40]  D. Mathews,et al.  Positron emission tomography in prostate and renal cell carcinoma , 2002, Current opinion in urology.

[41]  Sven Perner,et al.  Imaging prostate cancer with 11C-choline PET/CT. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[42]  J. Katzenellenbogen,et al.  Synthesis of high affinity fluorine-substituted ligands for the androgen receptor. Potential agents for imaging prostatic cancer by positron emission tomography. , 1992, Journal of medicinal chemistry.

[43]  O. Witte,et al.  Semi-quantification of methionine uptake and flair signal for the evaluation of chemotherapy in low-grade oligodendroglioma , 2004, Journal of Neuro-Oncology.

[44]  Koen Van Laere,et al.  Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[45]  D. Visvikis,et al.  In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography , 2003, Gut.

[46]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.

[47]  N. Goldstein,et al.  Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma , 2001, Cancer.

[48]  W. Vaalburg,et al.  Detection and Grading of Soft Tissue Sarcomas of the Extremities with 18F-3′-Fluoro-3′-Deoxy-l-Thymidine , 2004, Clinical Cancer Research.

[49]  R. Rosell,et al.  Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. , 2002, Biochemical and biophysical research communications.

[50]  Khaldoun Kerrou,et al.  PET/CT in patients with hepatocellular carcinoma using [18F]fluorocholine: preliminary comparison with [18F]FDG PET/CT , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[51]  B. Cheson,et al.  Positron-emission tomography and assessment of cancer therapy. , 2006, The New England journal of medicine.

[52]  M. Schwaiger,et al.  PET imaging with [18F]3′-deoxy-3′-fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[53]  Graeme Eisenhofer,et al.  6-[18F]Fluorodopamine Positron Emission Tomographic (PET) Scanning for Diagnostic Localization of Pheochromocytoma , 2001, Hypertension.

[54]  Sanjiv S Gambhir,et al.  PET of vascular endothelial growth factor receptor expression. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[55]  Matthias Reimold,et al.  18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancer , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[56]  P. Cutler,et al.  Preclinical evaluation of fluorine-18-labeled androgen receptor ligands in baboons. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[57]  J. Manola,et al.  Imaging kinase target inhibition with SU11248 by FDG-PET in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (I-R GIST) , 2005 .

[58]  J. Barrio,et al.  Imaging progress of herpes simplex virus type 1 thymidine kinase suicide gene therapy in living subjects with positron emission tomography , 2005, Cancer Gene Therapy.

[59]  M. Welch,et al.  Synthesis of 11 beta-[18F]fluoro-5 alpha-dihydrotestosterone and 11 beta-[18F]fluoro-19-nor-5 alpha-dihydrotestosterone: preparation via halofluorination-reduction, receptor binding, and tissue distribution. , 1995, Journal of medicinal chemistry.

[60]  W. Cai,et al.  Multimodality imaging of vascular endothelial growth factor and vascular endothelial growth factor receptor expression. , 2007, Frontiers in bioscience : a journal and virtual library.

[61]  D. Goeddel,et al.  Vascular endothelial growth factor is a secreted angiogenic mitogen. , 1989, Science.

[62]  Neal Rosen,et al.  Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors , 2004, Nature Biotechnology.

[63]  Gerald Reischl,et al.  PET with [18F]fluorothymidine for imaging of primary breast cancer: a pilot study , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[64]  Late resistance to imatinib therapy in a metastatic gastrointestinal stromal tumour is associated with a second KIT mutation , 2004, British Journal of Cancer.

[65]  Wolfgang A. Weber,et al.  Monitoring chemotherapy and radiotherapy of solid tumors , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[66]  Xavier Geets,et al.  Role of 11-C-methionine positron emission tomography for the delineation of the tumor volume in pharyngo-laryngeal squamous cell carcinoma: comparison with FDG-PET and CT. , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[67]  Wolfgang A Weber,et al.  Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  T. Shiga,et al.  Accumulation of [11C]acetate in normal prostate and benign prostatic hyperplasia: comparison with prostate cancer , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[69]  M. Merino,et al.  Localization of medullary thyroid carcinoma metastasis in a multiple endocrine neoplasia type 2A patient by 6-[18F]-fluorodopamine positron emission tomography. , 2003, The Journal of clinical endocrinology and metabolism.

[70]  Haesun Choi,et al.  Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  H D Humes,et al.  Carbon-11-acetate PET imaging in renal disease. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[72]  Mario Marengo,et al.  Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[73]  Otto Muzik,et al.  Imaging proliferation in vivo with [F-18]FLT and positron emission tomography , 1998, Nature Medicine.

[74]  Wolfgang A Weber,et al.  Monitoring cancer treatment with PET/CT: does it make a difference? , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[75]  A. Koong,et al.  Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[76]  J Nuyts,et al.  18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). , 2003, European journal of cancer.

[77]  C Burger,et al.  Quantitative PET studies in pretreated melanoma patients: a comparison of 6-[18F]fluoro-L-dopa with 18F-FDG and (15)O-water using compartment and noncompartment analysis. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[78]  P. Schnyder,et al.  The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[79]  J. Schipper,et al.  18F-DOPA positron emission tomography for the detection of glomus tumours , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[80]  A. D. Van den Abbeele,et al.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.

[81]  C. Pinson,et al.  11C-acetate: a new tracer for the evaluation of hepatocellular carcinoma. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[82]  I. Fogelman,et al.  The role of fluorodeoxyglucose, 18F-dihydroxyphenylalanine, 18F-choline, and 18F-fluoride in bone imaging with emphasis on prostate and breast. , 2006, Seminars in nuclear medicine.

[83]  J. Ajani,et al.  Early Detection of Chemoradioresponse in Esophageal Carcinoma by 3′-Deoxy-3′-3H-Fluorothymidine Using Preclinical Tumor Models , 2006, Clinical Cancer Research.

[84]  H. Barthel,et al.  Small-animal imaging of tumour proliferation with PET. , 2004, The Lancet. Oncology.

[85]  Michael E. Phelps,et al.  Usefulness of 3′-[F-18]Fluoro-3′-deoxythymidine with Positron Emission Tomography in Predicting Breast Cancer Response to Therapy , 2005, Molecular Imaging and Biology.

[86]  T. Hara,et al.  PET imaging of prostate cancer using carbon-11-choline. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[87]  Jae Jeong,et al.  Usefulness of 11C-methionine PET in the evaluation of brain lesions that are hypo- or isometabolic on 18F-FDG PET , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[88]  C. Degueldre,et al.  Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[89]  D. Visvikis,et al.  Potential impact of [18F]3'-deoxy-3'-fluorothymidine versus [18F]fluoro-2-deoxy-d-glucose in positron emission tomography for colorectal cancer , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[90]  V. Ambrosini,et al.  Role of 18F-dopa PET/CT imaging in the management of patients with 111In-pentetreotide negative GEP tumours , 2007, Nuclear medicine communications.

[91]  E. Van Cutsem,et al.  Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[92]  Sanjiv S. Gambhir,et al.  Gene therapy imaging in patients for oncological applications , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[93]  D. Karnofsky.  Meaningful clinical classification of therapeutic responses to anticancer drugs , 1961, Clinical pharmacology and therapeutics.

[94]  Sven N. Reske,et al.  Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[95]  J. Pruim,et al.  Visualization of prostate cancer with 11C-choline positron emission tomography. , 2002, European urology.

[96]  Sungeun Kim,et al.  11C-methionine PET as a prognostic marker in patients with glioma: comparison with 18F-FDG PET , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[97]  F. Shishido,et al.  Clinical value of pet with fluorine 18 fluorodeoxyglucose and l methyl carbon 11 methionine for diagnosis of recurrent brain tumor and radiation injury , 1991 .

[98]  C. Ceccarelli,et al.  Molecular determination of epidermal growth factor receptor in normal and neoplastic colorectal mucosa , 2006, British Journal of Cancer.

[99]  F. Shishido,et al.  Clinical Value of Pet with 18F-Fluorodeoxyglucose and L-Methyl-11C-Methionine for Diagnosis of Recurrent Brain Tumor and Radiation Injury , 1991, Acta radiologica.

[100]  T. Hara,et al.  Sensitive detection of mediastinal lymph node metastasis of lung cancer with 11C-choline PET. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[101]  H. Sugimura,et al.  Antitumor Effect of a Neutralizing Antibody to Vascular Endothelial Growth Factor on Liver Metastasis of Endocrine Neoplasm , 1998, Japanese journal of cancer research : Gann.

[102]  J. Nuyts,et al.  Fluoride kinetics of the axial skeleton measured in vivo with fluorine-18-fluoride PET. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[103]  R. Cerfolio,et al.  The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy. , 2005, The Journal of thoracic and cardiovascular surgery.

[104]  Otto S Hoekstra,et al.  Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[105]  Katsumasa Takahashi,et al.  Diagnosis of tumor in the nasal cavity and paranasal sinuses with [11C]choline PET: Comparative study with 2-[18F]fluoro-2-deoxy-d-glucose (FDG) PET , 2004, Annals of nuclear medicine.

[106]  Yoon-Koo Kang,et al.  Randomized phase III trial of sorafenib versus placebo in patients with advanced hepatocellular carcinoma (HCC) , 2007 .

[107]  R. Jain,et al.  Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer , 2007, Nature Clinical Practice Oncology.

[108]  C. Fuchs,et al.  A phase 2 study to evaluate the efficacy and safety of SU11248 in patients (pts) with unresectable neuroendocrine tumors (NETs) , 2005 .

[109]  Jinha M. Park,et al.  Reproducibility of 3'-deoxy-3'-(18)F-fluorothymidine microPET studies in tumor xenografts in mice. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[110]  E. Aboagye,et al.  Early detection of tumor response to chemotherapy by 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo. , 2005, Cancer research.

[111]  R. Bale,et al.  68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT , 2007, Journal of Nuclear Medicine.

[112]  R. Figlin,et al.  Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[113]  P. Malmström,et al.  Positron emission tomography with C11-acetate for tumor detection and localization in patients with prostate-specific antigen relapse after radical prostatectomy. , 2006, Urology.

[114]  M. Schwaiger,et al.  Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[115]  D. Heron,et al.  Posttreatment assessment of response using FDG-PET/CT for patients treated with definitive radiation therapy for head and neck cancers. , 2006, International journal of radiation oncology, biology, physics.

[116]  Jamal Zweit,et al.  Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. , 2002, Journal of the National Cancer Institute.

[117]  H. Mukai,et al.  Prospective study of positron emission tomography for evaluation of the activity of lapatinib, a dual inhibitor of the ErbB1 and ErbB2 tyrosine kinases, in patients with advanced tumors. , 2006, Japanese journal of clinical oncology.

[118]  Michael E. Phelps,et al.  Monitoring Tumor Glucose Utilization by Positron Emission Tomography for the Prediction of Treatment Response to Epidermal Growth Factor Receptor Kinase Inhibitors , 2006, Clinical Cancer Research.

[119]  W Vaalburg,et al.  Radiolabeled amino acids: basic aspects and clinical applications in oncology. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[120]  P. Catalano,et al.  Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[121]  S. Fanti,et al.  PET detection of epidermal growth factor receptor in colorectal cancer: a real predictor of response to cetuximab treatment? , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[122]  S. Zwas,et al.  PET/CT in the Evaluation of Response to Treatment of Liver Metastases from Colorectal Cancer with Bevacizumab and Irinotecan , 2006, Technology in cancer research & treatment.

[123]  J. Karstens,et al.  Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[124]  K Wienhard,et al.  Positron-emission tomography of vector-mediated gene expression in gene therapy for gliomas , 2001, The Lancet.

[125]  N. Sadato,et al.  11C-acetate PET imaging of prostate cancer. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[126]  I. Verma,et al.  Gene therapy - promises, problems and prospects , 1997, Nature.

[127]  E. Yoshikawa,et al.  Imaging of gynecologic tumors: comparison of (11)C-choline PET with (18)F-FDG PET. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[128]  S. Larson,et al.  Molecular Imaging of EGFR Kinase Activity in Tumors with 124I-Labeled Small Molecular Tracer and Positron Emission Tomography , 2006, Molecular Imaging and Biology.

[129]  H. Schirrmeister,et al.  F‐18 NaF PET for Detection of Bone Metastases in Lung Cancer: Accuracy, Cost‐Effectiveness, and Impact on Patient Management , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[130]  V. Sturm,et al.  11C-methionine and 18F-2-fluorodeoxyglucose positron emission tomography: a tool for diagnosis of cerebral glioma and monitoring after brachytherapy with 125I seeds. , 1997, Stereotactic and functional neurosurgery.

[131]  W. Negendank,et al.  Studies of human tumors by MRS: A review , 1992, NMR in biomedicine.

[132]  Gerald Antoch,et al.  Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[133]  Positive [11C]choline and negative [18F]FDG with positron emission tomography in recurrence of prostate cancer. , 2002, AJR. American journal of roentgenology.

[134]  E. Nitzsche,et al.  Combined FDG and [F-18]fluoride whole-body PET: a feasible two-in-one approach to cancer imaging? , 1998, Radiology.

[135]  K. Usadel,et al.  Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours , 1997, European Journal of Nuclear Medicine.

[136]  K. Takagishi,et al.  Carbon-11 Choline Positron Emission Tomography in Musculoskeletal Tumors: Comparison With Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography , 2003, Journal of computer assisted tomography.

[137]  V. Canzonieri,et al.  [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[138]  R L Wahl,et al.  Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[139]  H. Hoekstra,et al.  3'-18F-fluoro-3'-deoxy-L-thymidine: a new tracer for staging metastatic melanoma? , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[140]  Allan H Friedman,et al.  Phase II trial of gefitinib in recurrent glioblastoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[141]  D. Calne,et al.  The Use of Pet in Parkinsons-Disease , 1995, Brain and Cognition.

[142]  J. Talbot,et al.  Positron emission tomography with [18F]FDOPA and [18F]FDG in the imaging of small cell lung carcinoma: preliminary results , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[143]  Wolfgang A Weber,et al.  PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. , 2007, The Lancet. Oncology.

[144]  M. Berger,et al.  Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. , 2005, Journal of the National Cancer Institute.

[145]  B. Bernard,et al.  DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[146]  Roy Bicknell,et al.  The development of [(124)I]iodinated-VG76e: a novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomography. , 2002, Cancer research.

[147]  Wolfgang A Weber,et al.  Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[148]  R. Berardi,et al.  Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[149]  David Binns,et al.  Multi-tracer small animal PET imaging of the tumour response to the novel pan-Erb-B inhibitor CI-1033 , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[150]  Michael Bader,et al.  Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[151]  Marvin Bergsneider,et al.  Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[152]  R. Krais,et al.  Potential 18F-labeled biomarkers for epidermal growth factor receptor tyrosine kinase , 2001 .

[153]  D. Podoloff,et al.  The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[154]  S. Marnitz,et al.  Value of 18F-Fluoro-2-Deoxy-d-Glucose-Positron Emission Tomography/Computed Tomography in Non–Small-Cell Lung Cancer for Prediction of Pathologic Response and Times to Relapse after Neoadjuvant Chemoradiotherapy , 2006, Clinical Cancer Research.

[155]  Torsten Mattfeldt,et al.  Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[156]  G. Dresemann.  Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[157]  Masami Futatsubashi,et al.  11C-Choline Positron Emission Tomography in Prostate Cancer: Primary Staging and Recurrent Site Staging , 2005, Urologia Internationalis.

[158]  H. Schirrmeister,et al.  Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18)F-labeled NaF PET in newly diagnosed lung cancer. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[159]  E. Nitzsche,et al.  18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels , 2001, European Journal of Nuclear Medicine.

[160]  P F Sharp,et al.  Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[161]  Rodney J Hicks,et al.  Findings on 18F-FDG PET scans after neoadjuvant chemoradiation provides prognostic stratification in patients with locally advanced rectal carcinoma subsequently treated by radical surgery. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[162]  U. Metser,et al.  The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[163]  S. Yeh,et al.  11C-acetate clearance in nasopharyngeal carcinoma. , 1999, Nuclear medicine communications.

[164]  P. Schöffski,et al.  Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTATOC: preliminary data , 2001, European Journal of Nuclear Medicine.

[165]  V. Ambrosini,et al.  Diagnostic value of 68Ga-DOTANOC PET/CT in comparison to 18F-DOPA PET/CT: Preliminary report of seven MEN1 cases , 2007 .

[166]  Qimin He,et al.  3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. , 2003, Cancer research.

[167]  E. D. de Vries,et al.  Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study. , 2006, The Lancet. Oncology.

[168]  J. Wesseling,et al.  Comparison of 18F-FLT PET and 18F-FDG PET in esophageal cancer. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[169]  Mohan Doss,et al.  Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody. , 2005, Cancer research.

[170]  N. Ferrara,et al.  The biology of VEGF and its receptors , 2003, Nature Medicine.

[171]  K. Herholz,et al.  Monitoring the Effect of Chemotherapy in a Mixed Glioma by C‐11‐Methionine PET , 2003, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[172]  Joel Karp,et al.  Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[173]  L. Wiens,et al.  Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[174]  D. Visvikis,et al.  Assessment of recurrent colorectal cancer following 5-fluorouracil chemotherapy using both 18FDG and 18FLT PET , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[175]  C. Marosi,et al.  [11C] Methionine and [18F] Fluorodeoxyglucose PET in the follow-up of glioblastoma multiforme , 2007, Journal of Neuro-Oncology.

[176]  Reiman,et al.  9:30-9:45. Preliminary Evaluation of F-18 Fluorocholine (FCH) as a PET Tumor Imaging Agent. , 2000, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.

[177]  B. Beuthien-Baumann,et al.  [1-11C]Acetate uptake is not increased in renal cell carcinoma , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[178]  Georgios Karanikas,et al.  Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[179]  S. Cherry,et al.  Imaging of adenoviral-directed herpes simplex virus type 1 thymidine kinase reporter gene expression in mice with radiolabeled ganciclovir. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[180]  Eric O. Aboagye,et al.  Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[181]  Chi-Lai Ho,et al.  11C-acetate PET imaging in hepatocellular carcinoma and other liver masses. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[182]  H. Schirrmeister,et al.  Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[183]  Mithat Gonen,et al.  Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[184]  J. Nährig,et al.  Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[185]  J. Baselga.  The EGFR as a target for anticancer therapy--focus on cetuximab. , 2001, European journal of cancer.

[186]  J Kotzerke,et al.  Intraindividual comparison of [11C]acetate and [11C]choline PET for detection of metastases of prostate cancer , 2003, Nuklearmedizin.

[187]  S. Larson,et al.  Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[188]  Karl Herholz,et al.  Use of 11C-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[189]  K. Hess,et al.  Improved progression free survival (PFS), and rapid, sustained decrease in tumor perfusion among patients with advanced carcinoid treated with bevacizumab , 2005 .

[190]  Galith Abourbeh,et al.  High-affinity epidermal growth factor receptor (EGFR) irreversible inhibitors with diminished chemical reactivities as positron emission tomography (PET)-imaging agent candidates of EGFR overexpressing tumors. , 2005, Journal of medicinal chemistry.

[191]  J. Pruim,et al.  In vivo uptake of [11C]choline does not correlate with cell proliferation in human prostate cancer , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[192]  F. Fazio,et al.  Is 11C-choline the most appropriate tracer for prostate cancer? , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[193]  M J Welch,et al.  Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells. , 2001, Nuclear medicine and biology.

[194]  M. Schwaiger,et al.  Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[195]  A. D. Van den Abbeele,et al.  Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). , 2002, European journal of cancer.

[196]  H. Minn,et al.  Kinetics of [11C]choline uptake in prostate cancer: a PET stydy , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[197]  R. Tiling,et al.  Value of 11C-choline PET and PET/CT in patients with suspected prostate cancer , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[198]  H. Neumann,et al.  Pheochromocytomas: detection with 18F DOPA whole body PET--initial results.. , 2002, Radiology.

[199]  Cesare Guida,et al.  18F-FDG PET is an early predictor of pathologic tumor response to preoperative radiochemotherapy in locally advanced rectal cancer. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[200]  C. Perou,et al.  Molecular portraits and the family tree of cancer , 2002, Nature Genetics.

[201]  F Fazio,et al.  Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography. , 2003, The Journal of urology.

[202]  A. D. Van den Abbeele,et al.  Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[203]  V. Sturm,et al.  Glucose consumption and methionine uptake in low-grade gliomas after iodine-125 brachytherapy , 1996, European Journal of Nuclear Medicine.

[204]  H. Engler,et al.  Potential significance of 11C-methionine PET as a marker for the radiosensitivity of low-grade gliomas , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[205]  K. Herholz,et al.  Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. , 1999, European journal of cancer.

[206]  Y. Erdi,et al.  Tumor Localization of 16β-18F-Fluoro-5α-Dihydrotestosterone Versus 18F-FDG in Patients with Progressive, Metastatic Prostate Cancer , 2004 .

[207]  Nobuyuki Oyama,et al.  11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[208]  M Teräs,et al.  Radiotherapy treatment planning and long-term follow-up with [(11)C]methionine PET in patients with low-grade astrocytoma. , 2000, International journal of radiation oncology, biology, physics.

[209]  H. Dittmann,et al.  [18F]FLT PET for diagnosis and staging of thoracic tumours , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[210]  O. Witte,et al.  Positron emission tomography with injection of methionine as a prognostic factor in glioma. , 2001, Journal of neurosurgery.

[211]  L. Strauss,et al.  Exceptional increase in somatostatin receptor expression in pancreatic neuroendocrine tumour, visualised with 68Ga-DOTATOC PET , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[212]  A. Eberle,et al.  Receptor targeting for tumor localisation and therapy with radiopeptides. , 2000, Current medicinal chemistry.

[213]  S. Gambhir,et al.  PET imaging of herpes simplex virus type 1 thymidine kinase (HSV1-tk) or mutant HSV1-sr39tk reporter gene expression in mice and humans using [18F]FHBG , 2006, Nature Protocols.

[214]  Karl Herholz,et al.  18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[215]  J. Fowler,et al.  Synthesis and positron emission tomography studies of carbon-11-labeled imatinib (Gleevec). , 2007, Nuclear medicine and biology.

[216]  Howard Y. Chang,et al.  Decoding global gene expression programs in liver cancer by noninvasive imaging , 2007, Nature Biotechnology.

[217]  Mark Muzi,et al.  In vivo validation of 3'deoxy-3'-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[218]  M. Schwaiger,et al.  Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[219]  H. Sakahara,et al.  Evaluation of 3'-deoxy-3'-18F-fluorothymidine for monitoring tumor response to radiotherapy and photodynamic therapy in mice. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[220]  Isabelle Salmon,et al.  Comparison of 18F-FDG and 11C-methionine for PET-guided stereotactic brain biopsy of gliomas. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[221]  N. Shinoura,et al.  PET imaging of brain tumor with [methyl-11C]choline. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[222]  Angela Greco,et al.  A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. , 2004, Gastroenterology.

[223]  L. Weih,et al.  FDG-PET status following chemoradiotherapy provides high management impact and powerful prognostic stratification in oesophageal cancer , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[224]  C. Dence,et al.  Positron tomographic assessment of androgen receptors in prostatic carcinoma , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[225]  L. Mortelmans,et al.  [11C]methionine PET, histopathology, and survival in primary brain tumors and recurrence. , 2006, AJNR. American journal of neuroradiology.